Regulus Therapeutics (RGLS) microRNA Therapeutic Milestone Payment
Post# of 85
Posted On: 04/08/2015 12:20:38 AM
Keep a close eye on Regulus Therapeutics Inc. (RGLS), which said AstraZeneca (AZN) has selected the first clinical development candidate under the companies' strategic alliance, RG-125 (AZD4076), targeting microRNA-103/107 for the treatment of Non Alcoholic Steatohepatitis (NASH) in patients with type 2 diabetes/pre-diabetes.
In connection with the candidate selection, biopharmaceutical giant AstraZeneca will pay RGLS $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application.
Since the companies started their strategic alliance in 2012 to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology, AstraZeneca has paid $28.0 million (including an equity investment to RGLS, which also has earned a $2.5 million milestone payment for the above-mentioned clinical candidate selection and is eligible to receive up to $495.5 million in future milestone payments from AstraZeneca.
Shares of RGLS surged more than 10% Tuesday in extended-hours trading, following the announcement.
RGLS is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (small RNA molecules that do not encode proteins but instead regulate gene expression)
More about Regulus Therapeutics Inc. (RGLS) at www.regulusrx.com.
**
After the closing bell on Tuesday, Dave & Buster's Entertainment, Inc. (PLAY) reported strong quarterly financial results, with revenue and profit numbers that exceeded analysts' expectations.
For the fourth quarter 2014, PLAY posted revenues of $207.1 million, a 20.8% increase year over year, and non-GAAP net income of $14.1 million, or $0.33 per diluted share, compared to non-GAAP net income of $7.7 million, or $0.18 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus of $0.28 earnings per share on revenues of $204.25 million for the period
According to its business outlook for fiscal 2015, PLAY expects total revenues to be in the range of $808 million to $822 million and net income to be between $36.7 million and $40.4 million for the period.
PLAY is the leading owner and operator of high-volume venues that combine entertainment and dining in North America for both adults and families. The core of the concept is to offer customers the opportunity to "Eat Drink Play and Watch," all in one location.
More about Dave & Buster's Entertainment, Inc. (PLAY) at www.daveandbusters.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Hattiesburg, MS ( www.hattiesburg.ms.crwe-pr.com ) into the CRWE Network.
Hattiesburg is the fourth largest city in Mississippi. It is centrally located, about 90 minutes from the state capital of Jackson and roughly the same distance from New Orleans, Louisiana, and Mobile, Alabama.
The City of Hattiesburg had an estimated population in 2013 (U.S. Census Bureau) of 47,556, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
In connection with the candidate selection, biopharmaceutical giant AstraZeneca will pay RGLS $2.5 million and will assume development of the program following acceptance of an Investigational New Drug application.
Since the companies started their strategic alliance in 2012 to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology, AstraZeneca has paid $28.0 million (including an equity investment to RGLS, which also has earned a $2.5 million milestone payment for the above-mentioned clinical candidate selection and is eligible to receive up to $495.5 million in future milestone payments from AstraZeneca.
Shares of RGLS surged more than 10% Tuesday in extended-hours trading, following the announcement.
RGLS is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs (small RNA molecules that do not encode proteins but instead regulate gene expression)
More about Regulus Therapeutics Inc. (RGLS) at www.regulusrx.com.
**
After the closing bell on Tuesday, Dave & Buster's Entertainment, Inc. (PLAY) reported strong quarterly financial results, with revenue and profit numbers that exceeded analysts' expectations.
For the fourth quarter 2014, PLAY posted revenues of $207.1 million, a 20.8% increase year over year, and non-GAAP net income of $14.1 million, or $0.33 per diluted share, compared to non-GAAP net income of $7.7 million, or $0.18 per diluted share in the same quarter the prior year, topping the Capital IQ Consensus of $0.28 earnings per share on revenues of $204.25 million for the period
According to its business outlook for fiscal 2015, PLAY expects total revenues to be in the range of $808 million to $822 million and net income to be between $36.7 million and $40.4 million for the period.
PLAY is the leading owner and operator of high-volume venues that combine entertainment and dining in North America for both adults and families. The core of the concept is to offer customers the opportunity to "Eat Drink Play and Watch," all in one location.
More about Dave & Buster's Entertainment, Inc. (PLAY) at www.daveandbusters.com
**
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet. The company is currently developing its CRWE Network ( www.CRWE-PR.com ), a growing network of community targeted sites.
It has recently included the City of Hattiesburg, MS ( www.hattiesburg.ms.crwe-pr.com ) into the CRWE Network.
Hattiesburg is the fourth largest city in Mississippi. It is centrally located, about 90 minutes from the state capital of Jackson and roughly the same distance from New Orleans, Louisiana, and Mobile, Alabama.
The City of Hattiesburg had an estimated population in 2013 (U.S. Census Bureau) of 47,556, and represents an important marketplace for the CRWE Network, which business model is based on selling advertising to businesses targeting both locally and nationally
The CRWE Network has reached the 1487th community website in the U.S. and includes coverage in the states of California, Mississippi, Michigan, Florida, Nevada and New York, as well as across 10 provinces in Canada.
The company’s CRWE Press Release ( www.crwepressrelease.com ) offers increased visibility with cost effective solutions through the distribution of information to the entire CRWE Network for both public and private companies.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
**
Disclaimer: CRWE-PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
(0)
(0)AstraZeneca PLC (AZN) Stock Research Links
Scroll down for more posts ▼